Licensing Opportunity: Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses

This technology relates to a broadly protective, “universal” influenza vaccine candidate composed of a cocktail of different low pathogenicity avian influenza virus subtypes inactivated by betapropiolactone (BPL).

Like Comment

There is a great need for broadly protective, “universal” influenza virus vaccines given the antigenic drift and shift of influenza viruses and the variable protective efficacy of the current influenza vaccines. This technology relates to a broadly protective, “universal” influenza vaccine candidate composed of a cocktail of different low pathogenicity avian influenza virus subtypes inactivated by betapropiolactone (BPL). Vaccinating animals with BPL-inactivated whole virus vaccine comprising influenza virus strains belonging to four or more different low pathogenicity avian influenza hemagglutinin subtypes, intranasally or intramuscularly, provided extremely broad protection and heterosubtypic protection to lethal challenge with influenza viruses in both mice and ferrets. This influenza vaccine technology has a great potential to offer broad protection against both seasonal and pandemic-potential influenza viruses.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. 

Potential Commercial Applications: 

•Vaccine against viruses

•Vaccines against influenza virus

•Universal influenza virus vaccine

Competitive Advantages: 

•Broad protection to both seasonal and pandemic-potential influenza viruses

•Easy and cost-effective inactivation method

•Effective immune response due to the use of authentic viral antigens

•Animal data available

Development Stage: 

•In vivo (animal)

Intellectual Property:  

HHS Reference No. E-033-2018/0 – PCT Application filed January 18, 2019 – PCT/US2019/014220

Licensing Contact: 

To license this technology, please contact Jenish Patel, Ph.D., 240-669-2894; jenish.patel@nih.gov 

Go to the profile of NIAID Technology Transfer and Intellectual Property Office

NIAID Technology Transfer and Intellectual Property Office

NIAID’s technology transfer office, TTIPO, is a one-stop resource for organizations interested in partnering with NIAID to access, develop, and manage the translation of research discoveries into medically beneficial products. TTIPO seeks to expand NIAID’s innovation pipeline with existing and new partners in areas such as newly emerging and re-emerging infectious diseases (e.g., dengue, Zika, Ebola, influenza, methicillin-resistant Staphylococcus aureus and HIV/AIDS), biodefense (e.g., smallpox and anthrax), and immune-mediated diseases (e.g., asthma and allergy).

No comments yet.